MAPT and Cognitive impairment: Clinical studies have reported improved cognitive outcome following n-3 PUFA administration, particularly in individuals with a mild cognitive impairment, but they provide no clear evidence of the superiority of EPA versus DHA (4, 49, 50) and of any impact on tau pathology.